4G8 Stock Overview
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Guerbet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.90 |
| 52 Week High | €39.40 |
| 52 Week Low | €17.56 |
| Beta | 0.80 |
| 1 Month Change | 12.96% |
| 3 Month Change | -19.94% |
| 1 Year Change | 43.81% |
| 3 Year Change | -20.96% |
| 5 Year Change | -29.63% |
| Change since IPO | -12.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4G8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.5% | 2.1% | 2.0% |
| 1Y | 43.8% | -7.9% | 9.6% |
Return vs Industry: 4G8 exceeded the German Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: 4G8 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 4G8 volatility | |
|---|---|
| 4G8 Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4G8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4G8's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,920 | David Hale | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
Guerbet SA Fundamentals Summary
| 4G8 fundamental statistics | |
|---|---|
| Market cap | €356.20m |
| Earnings (TTM) | €32.76m |
| Revenue (TTM) | €840.79m |
10.9x
P/E Ratio0.4x
P/S RatioIs 4G8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4G8 income statement (TTM) | |
|---|---|
| Revenue | €840.79m |
| Cost of Revenue | €211.73m |
| Gross Profit | €629.06m |
| Other Expenses | €596.30m |
| Earnings | €32.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 2.60 |
| Gross Margin | 74.82% |
| Net Profit Margin | 3.90% |
| Debt/Equity Ratio | 98.3% |
How did 4G8 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 22:33 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guerbet SA is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurent Gelebart | BNP Paribas Exane |
| Arnaud Cadart | CIC Market Solutions (ESN) |
| Robin Leclerc | Degroof Petercam |